CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were first identified as disease-causing in 2004. CDD was previously not considered as a separate indication; rather, it was assumed to be an atypical form of Rett Syndrome. The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development. The condition was previously known as serine/threonine-protein kinase 9 (STK9), and it has been classified as DEE because the genetic change causes epileptic activity as well as severe impairment of the development. The CDKL5 gene is located on the X chromosome. The X chromosome is one of the sex chromosomes; females have two X’s, and males have one X and one Y chromosome. Although many identified patients are males, because of the location of the gene, this disorder mainly affects females. Affected males may have more severe symptoms than females.
This report contains market size and forecasts of CDKL5 Deficiency Disorder (CDD) in Global, including the following market information:
Global CDKL5 Deficiency Disorder (CDD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global CDKL5 Deficiency Disorder (CDD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Traditional Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of CDKL5 Deficiency Disorder (CDD) include Marinus Pharmaceuticals, Ovid Therapeutics/Takeda, Zogenix and PTC Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CDKL5 Deficiency Disorder (CDD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CDKL5 Deficiency Disorder (CDD) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global CDKL5 Deficiency Disorder (CDD) Market Segment Percentages, by Type, 2021 (%)
Traditional Drugs
Emerging Drugs
Global CDKL5 Deficiency Disorder (CDD) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global CDKL5 Deficiency Disorder (CDD) Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global CDKL5 Deficiency Disorder (CDD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global CDKL5 Deficiency Disorder (CDD) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CDKL5 Deficiency Disorder (CDD) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies CDKL5 Deficiency Disorder (CDD) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Marinus Pharmaceuticals
Ovid Therapeutics/Takeda
Zogenix
PTC Therapeutics